BALAXI PHARMACEUTICALS share news, announcements and annual reports
NSE: BALAXIPharmaceuticals & BiotechnologySmall Cap
BALAXI PHARMACEUTICALS LIMITED · Formerly Balaxi Ventures · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Nov 2015
Last close ₹19.15down ₹0.56 (2.84%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹19.71.
30 Oct: open ₹19.99, high ₹19.99, low ₹18.70
52-week range of traded prices to 30 Oct 2026
₹15.20Low, 27 Mar 2026₹43.85High, 4 Nov 2025
- Next results date: the board meets on 12 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹106 Cr2,722nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 43.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.42
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 1.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.22
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 21,37768.9% delivered
BALAXI PHARMACEUTICALS share news and announcements
466 announcements, routine notices left out, newest first. Page 6 of 10.
Apr 2021
14 Apr · Board meeting
9 Apr · Board meeting
Mar 2021
26 Mar · Management
10 Mar · Legal
Exchange has sought clarification from BALAXI PHARMACEUTICALS LIMITED with respect to announcement dated 02-Mar-2021, regarding resignation of Mr. Rakesh Khanna. On basis of above the Company is required to clarify following: 1. No other material reasons other than provided The response of the Company is awaited.3 Mar · Analysts
2 Mar · Management
Jan 2021
19 Jan · Results
19 Jan · Board meeting
12 Jan · Board meeting
Nov 2020
10 Nov · Related Party Transactions
Oct 2020
29 Oct · Analysts
18 Oct · Analysts
15 Oct · Updates
14 Oct · Name Change
Members of the Exchange are hereby informed that the name of Balaxi Ventures Limited shall be changed to BALAXI PHARMACEUTICALS LIMITED w.e.f. October 20, 2020.12 Oct · Board meeting
12 Oct · Results
Sep 2020
2 Sep · Legal
Exchange has sought clarification from Balaxi Ventures Limited with respect to announcement dated 27-Aug-2020, regarding a press release dated August 27, 2020, titled "BALAXI VENTURES LIMITED ANNOUNCES ACQUISITION OF 49% STAKE IN GROUP'S ANGOLA BASED DISTRIBUTION ARM. On basis of above the Company is required to clarify following: 1. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";2. Brief details of any governmental or regulatory approvals required for the acquisition;3. Indicative time period for completion of the acquisition;4. Cost of acquisition or the price at which the shares are acquired;5. Nature of consideration - whether cash consideration or share swap and details of the same;6. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).The response of the Company is awaited.
Aug 2020
Jul 2020
22 Jul · Board meeting
22 Jul · Results
14 Jul · Board meeting
Jun 2020
19 Jun · Related Party Transactions
17 Jun · Corrigendum